NIPA1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | NIPA1, FSP3, SPG6, non imprinted in Prader-Willi/Angelman syndrome 1, SLC57A1, NIPA magnesium transporter 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 608145 MGI: 2442058 HomoloGene: 42327 GeneCards: NIPA1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Non-imprinted in Prader-Willi/Angelman syndrome region protein 1 is a protein that in humans is encoded by the NIPA1 gene.[5][6] This gene encodes a potential transmembrane protein which functions either as a receptor or transporter molecule, possibly as a magnesium transporter.[7] This protein is thought to play a role in nervous system development and maintenance. Alternative splice variants have been described, but their biological nature has not been determined. Mutations in this gene have been associated with the human genetic disease autosomal dominant spastic paraplegia 6.[8][9]
References
- 1 2 3 ENSG00000288478 GRCh38: Ensembl release 89: ENSG00000170113, ENSG00000288478 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000047037 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ Rainier S, Chai JH, Tokarz D, Nicholls RD, Fink JK (Sep 2003). "NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6)". Am J Hum Genet. 73 (4): 967–71. doi:10.1086/378817. PMC 1180617. PMID 14508710.
- ↑ "Entrez Gene: NIPA1 non imprinted in Prader-Willi/Angelman syndrome 1".
- ↑ Goytain A, Hines RM, El-Husseini A, Quamme GA (2007). "NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter". J. Biol. Chem. 282 (11): 8060–8. doi:10.1074/jbc.M610314200. PMID 17166836.
- ↑ Reed JA, Wilkinson PA, Patel H, et al. (2005). "A novel NIPA1 mutation associated with a pure form of autosomal dominant hereditary spastic paraplegia". Neurogenetics. 6 (2): 79–84. doi:10.1007/s10048-004-0209-9. PMID 15711826. S2CID 2236413.
- ↑ Rainier S, Chai JH, Tokarz D, et al. (2003). "NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6)". Am. J. Hum. Genet. 73 (4): 967–71. doi:10.1086/378817. PMC 1180617. PMID 14508710.
Further reading
- Bittel DC, Kibiryeva N, Butler MG (2006). "Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi syndrome". Pediatrics. 118 (4): e1276–83. doi:10.1542/peds.2006-0424. PMC 5453799. PMID 16982806.
- Liu T, Qian WJ, Gritsenko MA, et al. (2006). "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry". J. Proteome Res. 4 (6): 2070–80. doi:10.1021/pr0502065. PMC 1850943. PMID 16335952.
- Munhoz RP, Kawarai T, Teive HA, et al. (2006). "Clinical and genetic study of a Brazilian family with spastic paraplegia (SPG6 locus)". Mov. Disord. 21 (2): 279–81. doi:10.1002/mds.20775. PMID 16267846. S2CID 21070143.
- Chen S, Song C, Guo H, et al. (2006). "Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families". Hum. Mutat. 25 (2): 135–41. doi:10.1002/humu.20126. PMID 15643603. S2CID 5773016.
- Chai JH, Locke DP, Greally JM, et al. (2003). "Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons". Am. J. Hum. Genet. 73 (4): 898–925. doi:10.1086/378816. PMC 1180611. PMID 14508708.
- Toyoda N, Nagai S, Terashima Y, et al. (2003). "Analysis of mRNA with microsomal fractionation using a SAGE-based DNA microarray system facilitates identification of the genes encoding secretory proteins". Genome Res. 13 (7): 1728–36. doi:10.1101/gr.709603. PMC 403746. PMID 12805275.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Fink JK, Jones SM, Sharp GB, et al. (1996). "Hereditary spastic paraplegia linked to chromosome 15q: Analysis of candidate genes". Neurology. 46 (3): 835–6. doi:10.1212/wnl.46.3.835. PMID 8618696. S2CID 39414032.
- Fink JK, Wu CT, Jones SM, et al. (1995). "Autosomal dominant familial spastic paraplegia: tight linkage to chromosome 15q". Am. J. Hum. Genet. 56 (1): 188–92. PMC 1801321. PMID 7825577.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.